Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on October 23, 2026 reporting Item 8.01 (Other Events). BDR sued FDA over alleged refusal to accept an ANDA referencing VOQUEZNA tablets.
Phathom Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- BDR sued FDA over alleged refusal to accept an ANDA referencing VOQUEZNA tablets
- FDA-recognized NCE exclusivity runs through May 3, 2032, supporting Phathom’s expected protection from generic competition
- Adverse ruling could shorten exclusivity and allow earlier FDA review or approval of competing ANDAs
- Litigation creates potential risks to VOQUEZNA sales, stock price, management focus and financial prospects
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Phathom Pharmaceuticals, Inc. 8-K filings
Get the next PHAT 8-K as it lands
Follow PHAT for push alerts, or ask the research agent what this filing means.